Giammarino’s care was covered by the federally funded WTC Health Program, according to Northwell Health. Of the nearly 137,000 current members of the WTC ...

Columnist Caroline Gainer experiences relentless fatigue, chills, and sweating, possibly from COPD and/or chronic ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

The likelihood for mortality during hospitalization was increased among those with COPD or asthma vs. asthma-COPD overlap ...

DWP figures show there are 178 different conditions that people have which is allowing them to claim Personal Independence ...

PIP pays varying amounts depending on the claimant's needs. There are payments for everyday activities and a separate amount ...

Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...

Drug developer aTyr Pharma's experimental drug failed to meet the main goal in a late-stage study for the treatment of a type ...

(Reuters) - aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing ...